Impact Factor: 1.8

Open Access Published since March 20, 2016

Pleura and Peritoneum

Official Journal of the International Society for the Study of Pleura and Peritoneum

ISSN: 2364-768X

Editor-in-chief: Marc A. Reymond

Edited by: Frédéric Bibeau, Wim Ceelen, Ben Davidson, Marc Pocard, Clemens B. Tempfer

Submit manuscript

About this journal

Objective: Peritoneal and pleural infections and oncological diseases often result in life-threatening conditions. However, the pleura (serous membrane, which forms the lining of the pleural cavity) and the peritoneum (serous membrane, which forms the lining of the abdominal cavity) have been relatively poorly studied, as compared to other organs. In sharp contrast to the skin, which is recognized as an organ and object of a medical specialty, pleura and peritoneum are only considered as membranes. This might be explained by the fact that these organs cannot be seen, neither by clinical examination nor by radiological methods. Pleura and Peritoneum wants to change this by creating a high-level exchange platform for basic scientists, clinical researchers and physicians – an unmet need so far.

Pleura and Peritoneum is an open access journal, focusing on the organs pleura and peritoneum. It is the official journal of the International Society for the Study of Pleura and Peritoneum (ISSPP). The journal is issued quarterly. All contributions submitted for publication are single-blind peer reviewed by at least two renowned experts in the field, selected and invited by the Editor-in-Chief. All submissions will be subject to a rapid peer-review process, allowing a first decision within 3-4 weeks of submission. Pleura and Peritoneum publishes only English-language articles and accepts research articles and short communications of experimental and clinical results, and biochemical and anatomical findings, and reviews, mini reviews, opinion papers and editorials.

All information on article processing charges can be found at the corresponding link under Supplementary Materials.

Please submit your manuscript here

Topics

Diagnosis and treatment of diseases of the human organs pleura and peritoneum
Pleural effusions
Laparoscopy
Thoracoscopy
Surgery
Gynecology
Imaging
Oncological diseases
Anatomy
Cytology
Gene therapy
Radiotherapy
Systemic drug therapy

Article formats

Research Articles – Reports of original research
Review Articles – Systematic, narrative, and focused reviews. Review Articles are normally published by invitation, but suggestions to the Editors are welcome
Opinion Papers
Point/Counterpoint Papers
Editorials
Letters to the Editor
Clinical Images
Short Communications – Reports of early research results and pilot studies

Your Benefits

Your Benefits

Innovative and groundbreaking approach to the study of the pleura and peritoneum
Interdisciplinary approach to the subject matter
Cutting-edge and authoritative contributions
Renowned international editors and editorial board
Publication under the Creative Commons Attribution (CC-BY-4.0) License

History

New journal at De Gruyter

Other publications in the field

Innovative Surgical Sciences

Diagnosis

Abstracting and Indexing

Pleura and Peritoneum is covered by the following services:

Baidu Scholar
Cabells Journalytics
Chronos Hub
CNKI Scholar (China National Knowledge Infrastructure)
CNPIEC - cnpLINKer
Dimensions
DOAJ (Directory of Open Access Journals)
EBSCO Discovery Service
EMBASE
GoOA
Google Scholar
Indextra (Medical Library)
J-Gate
JournalTOCs
KESLI-NDSL (Korean National Discovery for Science Leaders)
MyScienceWork
Naver Academic
Naviga (Softweco)
Primo Central (ExLibris)
Publons
PubMed
PubMed Central
QOAM (Quality Open Access Market)
ReadCube
Scilit
SCImago (SJR)
SCOPUS
Semantic Scholar
Sherpa/RoMEO
Summon (ProQuest)
TDNet
Text Mining
Ulrich's Periodicals Directory/ulrichsweb
WanFang Data
Web of Science - Emerging Sources Citation Index
WorldCat (OCLC)
X-MOL
Yewno Discover

Supplementary Materials

Topics

External Links

Volume 9 Issue 1

March 2024

Publicly Available April 1, 2024

Frontmatter

Page range: i-ii

Download PDF

Review

Open Access March 13, 2024

Outcomes of minimal access cytoreductive surgery (M-CRS) and HIPEC/EPIC vs. open cytoreductive surgery (O-CRS) and HIPEC/EPIC in patients with peritoneal surface malignancies: a meta-analysis

Ajinkya Pawar, Vikas Warikoo, Abhijeet Salunke, Mohit Sharma, Shashank Pandya, Amol Bhardwaj, Sandeep KS, Jebin Aaron

Page range: 1-13

More Download PDF

Abstract

Introduction Minimal Access Surgery (MAS) has shown better peri-operative outcomes with equivalent oncological outcomes in gastrointestinal and thoracic oncology. Open CRS (O-CRS) procedure accompanies inevitable and significant surgical morbidity in patients. The aim of the review article is to compare outcomes of M-CRS and HIPEC/EPIC with open procedure in peritoneal surface malignancies. Content Comprehensive search of databases was done and total 2,807 articles were found (2793-PubMed and 14-Cochrane review). PRISMA flow chart was prepared and 14 articles were selected. Meta-analysis was performed according to PRISMA guidelines using random-effects model (DerSimonian Laird) and fixed effect model. Publication bias was tested with Funnel plot and Egger’s regression test. Quality of studies was assessed by Newcastle–Ottawa scale. Summary and Outlook Patients in both groups [total (732), M-CRS(319), O-CRS(413)] were similar in demographic characteristics. Peri-operative outcomes were significantly better in M-CRS group in terms of blood loss SMD=−2.379, p<0.001 (95 % CI −2.952 to −1.805), blood transfusion RR=0.598, p=0.011 (95 % CI 0.402 to 0.889), bowel recovery SMD=−0.843, p=0.01 (95 % CI −1.487 to −0.2), hospital stay SMD=−2.348, p<0.001 (95 % CI −3.178 to −1.519) and total morbidity RR=0.538, p<0.001 (95 % CI 0.395 to 0.731). Duration of surgery SMD=−0.0643 (95 % CI −0.993 to 0.865, p=0.892) and CC0 score RR=1.064 (95 % CI 0.992 to 1.140, p=0.083) had no significant difference. Limited studies which evaluated survival showed similar outcomes. This meta-analysis shows that M-CRS and HIPEC/EPIC is feasible and has better peri-operative outcomes compared to open procedure in patients with limited peritoneal carcinoma index (PCI) peritoneal surface malignancies. Survival outcomes were not calculated. Further studies are warranted in this regard.

Research Articles

Open Access December 27, 2023

Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)

Luis Felipe Falla-Zuniga, Armando Sardi, Mary Caitlin King, Felipe Lopez-Ramirez, Philipp Barakat, Carol Nieroda, Teresa Diaz-Montes, Vadim Gushchin

Page range: 15-22

More Download PDF

Abstract

Objectives There are limited treatment options and no consensus on the management of advanced rare ovarian malignancies. Rare ovarian malignancies can present with peritoneal metastases (PM), featuring a similar presentation to more common ovarian subtypes. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is an effective treatment for PM of non-gynecologic origin and, recently, epithelial ovarian cancer. We evaluated the feasibility of CRS/HIPEC in the management of PM from rare ovarian malignancies and report postoperative outcomes on these patients. Methods A retrospective review of a single center, prospective database (1994–2021) was performed to identify patients with rare ovarian malignancies treated with CRS/HIPEC. Clavien-Dindo 90-day morbidity/mortality and Kaplan–Meier overall (OS) and progression-free survival (PFS) were analyzed. Results Of 44 patients identified, 28 underwent CRS/HIPEC. Six were aborted due to extensive disease. Histologic subtypes included: clear cell (5/28, 17.9 %), endometrioid (5/28, 17.9 %), granulosa cell (3/28, 10.7 %), low-grade serous (6/28, 21.4 %), mesonephric (1/28, 3.6 %), mucinous (6/28, 21.4 %), and small cell (2/28, 7.1 %) carcinomas. Eight (28.6 %) patients had primary and 20 (71.4 %) had recurrent disease. Median peritoneal cancer index (PCI) was 21 (IQR: 6–29). Complete cytoreduction (<2.5 mm residual disease) was achieved in 27/28 (96.4 %). Grade III/IV complications occurred in 9/28 (32.1 %) with one (3.6 %) mortality. After a median follow-up of 65.8 months, 20 patients were alive. Five-year OS and PFS were 68.5 and 52.6 %, respectively. Conclusions In patients with PM from rare ovarian malignancies, CRS/HIPEC is feasible and has an acceptable safety profile. Longer follow-up and multicenter trials are needed.

Open Access February 28, 2024

In vitro 3D microfluidic peritoneal metastatic colorectal cancer model for testing different oxaliplatin-based HIPEC regimens

Aras Emre Canda, Tolga Sever, Gizem Calibasi Kocal, Yasemin Basbinar, Hulya Ellidokuz

Page range: 23-29

More Download PDF

Abstract

Objectives Treatment of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) is still evolving. Conducting a randomized trial is challenging due to the high heterogeneity in the presentation of peritoneal disease and various surgical approaches. Biological research may facilitate more rapid translation of information into clinical practice. There is an emerging need for a preclinical model to improve HIPEC treatment protocols in terms of drug doses and treatment durations. The aim of the study is to design a tool that serves as an in vitro three-dimensional (3D) microfluidic peritoneal metastatic colorectal cancer model to test the efficacy of different HIPEC treatments. Methods We determined the effects of current therapy options using a 3D static disease model on human colon carcinoma cell lines (HCT 116) and transforming growth factor-β1 induced epithelial-to-mesenchymal transition (EMT) HCT 116 lines at 37 °C and 42 °C for 30, 60, and 120 min. We determined oxaliplatin’s half maximal inhibitory concentrations in a 3D static culture by using viability assay. Clinical practices of HIPEC were applied in the developed model. Results EMT-induced HCT 116 cells were less sensitive to oxaliplatin treatment compared to non-induced cells. We observed increased cytotoxicity when increasing the temperature from 37 °C to 42 °C and extending the treatment duration from 30 to 120 min. We found that 200 mg/m 2 oxaliplatin administered for 120 min is the most effective HIPEC treatment option within the framework of clinic applications. Conclusions The tool map provide insights into creating more realistic pre-clinical tools that could be used for a patient-based drug screening.

Open Access December 29, 2023

Active surveillance for low-grade appendiceal mucinous neoplasm (LAMN)

Christian Mouawad, Armelle Bardier, Mathilde Wagner, Solène Doat, Dahbia Djelil, Jade Fawaz, Marc Pocard

Page range: 31-37

More Download PDF

Abstract

Objectives Due to the scarcity of low-grade appendiceal mucinous neoplasm (LAMN), there is an absence of systematized guidelines concerning its management, especially after incidental finding on an appendiceal specimen. In this study, we evaluate the active surveillance (AS) strategy adopted for a series of patients diagnosed with LAMN on resection specimens who were considered to have a low risk of pseudomyxoma progression. Methods Thirty patients were included between April 2014 and July 2021, with a female majority and a median follow-up period of 3.1 years. The inclusion criteria were as follows: LAMN diagnosis on appendiceal specimens, confirmed in an expert center, limited extra-appendiceal mucin resected and localized around the appendix, normal biology (CEA, CA199, CA125) and normal abdominopelvic MRI. AS included physical exam (trocar scar), biology and MRI, 6 months postoperatively, then yearly for 10 years. Results As an initial surgery, 77 % had an appendectomy as their initial intervention, 17 % had a cecectomy, and 6 % had a right colectomy. After follow-up, 87 % of patients showed no sign of disease progression by MRI, while 13 % progressed to PMP. MRI performed in the first postoperative year predicted the disease prognosis in 97 % of patients. Conclusions The AS strategy, based on MRI, is a valid option after incidental LAMN diagnosis.

Open Access February 28, 2024

Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP

Selin Küçükyurt, Tuğçe Eşkazan, Mesut Ayer, Burçak Kılıçkıran Avcı, İbrahim Hatemi, Ahmet Emre Eşkazan

Page range: 39-43

More Download PDF

Abstract

Objectives Pleural effusion (PE) is the most frequent pulmonary complication of dasatinib, a tyrosine kinase inhibitor (TKI). Concurrent pericardial effusions have been reported in about one-third of the cases. In this study, we aimed to investigate ascites generation in chronic-phase chronic myeloid leukemia (CML-CP) patients developing PE under dasatinib. Methods We conducted a cross-sectional study to evaluate whether pericardial effusion and ascites accompany PE in CML-CP patients treated with dasatinib. For this purpose, consecutive patients with CML-CP who developed PE under dasatinib therapy have been evaluated with chest X-ray, transthoracic echocardiography, and abdominal ultrasonography. Results There were seven patients, and the median age was 50 years (range, 31–73 years). Most of patients were male (n=5). All patients received imatinib as first-line TKI. Six patients received dasatinib following imatinib failure in second line. The median duration from dasatinib initiation to PE generation was 58 months (range, 8–135 months). Consequently, four patients had grade 1 pericardial effusion, and no patient had ascites. Conclusions In our small study, dasatinib-related PE was associated with low-grade pericardial effusion but no ascites. There are hypothetical explanations of this phenomenon including the simultaneous activation/inhibition of kinases; however, more research needs to be performed on this topic.

Letter to the Editor

Open Access December 20, 2023

Implementation of ERAS guidelines in patients undergoing CRS and HIPEC: need for multicentre trial

Christos Iavazzo, Ioannis D. Gkegkes, John Spiliotis

Page range: 45-46

Download PDF

Ahead of Print / Just Accepted

Ahead of Print / Just Accepted

Volume 9 (2024)

Issue 1

Volume 8 (2023)

Volume 7 (2022)

Volume 6 (2021)

Volume 5 (2020)

Volume 4 (2019)

Volume 3 (2018)

Volume 2 (2017)

Volume 1 (2016)

Journal Impact Factor	1.8	2022, Journal Citation Reports (Clarivate, 2023)
5-year Journal Impact Factor	2.8	2022, Journal Citation Reports (Clarivate, 2023)
Journal Citation Indicator	0.52	2022, Journal Citation Reports (Clarivate, 2023)
CiteScore	2.8	2022, Scopus (Elsevier B.V., 2023)
SCImago Journal Rank	0.449	2022, SJR (Scimago Lab, 2023; Data Source: Scopus)
Source Normalized Impact per Paper	0.692	2022, CWTS Journal Indicators (CWTS B.V., 2023; Data Source: Scopus)

More information about journal rankings

Submit

Submission

You can easily submit your manuscript online. Simply go to https://mc.manuscriptcentral.com/pap and you will be guided through the whole submission and publishing process.

Your benefits of publishing with us

Rapid publication times
The article processing charge (APC) for the publication of an article is € 1,000. All information on APCs can be found at the: Article Processing Charges.
Open Access - research freely available for all to read and download
Authors retain copyright – articles published under the Creative Commons Attribution (CC-BY-4.0) License
Each article easily discoverable because of SEO and comprehensive abstracting and indexing services
Secure archiving by De Gruyter and the independent archiving service Portico

Submission process

Submission of your manuscript via our submission management tool following the Information for Authors
Single-blind peer review process
A decision on your paper is aspired within 3-4 weeks
Accepted articles are published online ahead of print approx. 2-3 weeks after acceptance

Please note

Manuscripts must be written in clear and concise English
Before submitting your article please have a look at the Submission Checklist and Publication Ethics Statement
The License to Publish must be filled in and signed, and submitted as separate file
As a condition of submission, the Template for Ethical and Legal Declarations must be customized by the submitting author on behalf of all others and uploaded as a separate Word file. Instructions on how to make declarations can be found here
If you have any general questions please visit our FAQ page for authors
For more detailed information please contact the Editorial Office of Pleura and Peritoneum at pap.editorial@degruyter.com

We look forward to receiving your manuscript!

Editorial

Editor in Chief
Marc A. Reymond, University Hospital, Department of Surgery and Transplantation, Tübingen, Germany

Associate Editors
Frédéric Bibeau, University of Montpellier, Montpellier, France
Wim Ceelen, Ghent University, Ghent, Belgium
Ben Davidson, University of Oslo, Oslo, Norway
Marc Pocard, University Paris Diderot, Paris, France
Clemens B. Tempfer, Ruhr-University Bochum, Bochum, Germany

Editorial Board
Katalin Dobra, Karolinska University, Stockholm, Sweden
Ambrogio Fassina, University of Padova, Padova, Italy
Diane Goéré, Institut Gustave Roussy, Cancer Center, Villejuif, France
Sarah Herrick, The University of Manchester, Manchester, UK
Kazuho Honda, Showa University School of Medicine, Tokyo, Japan
Masato Kanzaki, Tokyo Women’s Medical University, Tokyo, Japan
Kunio Kawanishi, University of California, San Diego, CA, USA
Laura Lambert, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
Ulrich Lauer, University of Tübingen, Tübingen, Germany
Maurie Markman, Cancer Treatment Centers of America, Philadelphia, PA, USA
Amit Merchea, Jacksonville, FL, USA
Claire W. Michael, Case Western Reserve University Cleveland, OH, USA
Faheez Mohamed, Hampshire Hospitals, NHS, Basingstoke, UK
Steve Mutsaers, University of Western Australia, Perth, Australia
Martin K. Oehler, Royal Adelaide Hospital, Adelaide, Australia
Kurt Van der Speeten, Ziekenhuis Oost Limburg, Genk, Belgium
Wei Peng Yong, National University Hospital Singapore, Singapore

Executive Secretary
Wiebke Solass
University Hospital Tübingen
Tübingen, Germany
E-mail: wiebke.solass@t-online.de

Editorial Office
Heike Jahnke
Walter de Gruyter GmbH
Genthiner Str. 13
10785 Berlin
Germany
Tel. +49-30-26005-220
Fax: +49-30-26005-184
E-mail: pap.editorial@degruyter.com

(Deutsch)

Type: Journal
Language: English
Publisher: De Gruyter
First published: March 20, 2016
Publication Frequency: 4 Issues per Year
Audience: Basic scientists, clinical researchers, and physicians
Keywords: Medicine, Surgery, Oncology